Percutaneous coronary intervention in patients with peripheral artery disease and adverse cardiovascular adverse event and bleeding. (14th October 2021)

• Record Type: Journal Article
• Authors: Kang, M G; Kim, K H; Park, H W; Koh, J S; Hwang, S J; Hwang, J Y; Park, J R
• Is Part Of: European heart journal. Volume 42(2021)Supplement 1
• Publication Date: 2021-10-14
• Subjects: Epidemiology, Prognosis, Outcome; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehab724.1149
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Background: Peripheral artery disease (PAD) increase the risk of comorbidity and mortality in coronary artery disease (CAD). Objectives: We evaluate influence of PAD on prognosis in patients undergoing percutaneous coronary intervention (PCI). Methods: We analyzed all consecutive patients included in our dedicated local registry for PCI between January 2011 and December 2016. Presence of PAD was defined by decreased ankle-brachial index (<0.9). Major adverse cardiovascular event (MACE) was defined as a composite of cardiovascular death, non-fatal myocardial infarct, revascularization, and ischemic stroke. Major bleeding was defined as Bleeding Academic Research Consortium 3 or 5. Results: Among the 4, 747 patients who underwent the PCI, 12.9% (n=610) of PAD were identified. Old age (>60 years), renal dysfunction, reduced ejection fraction, and presence of PAD were predictors with both MACE and major bleeding event. Among them, presence of PAD was an independent risk factor of MACE and major bleeding (MACE, HR 8.26, 95% CI 2.33- 29.41, p=0.036; major bleeding, HR 3.11, 95% CI 1.10–10.63, p=0.040, respectively). The MACE and major bleeding rate at 5-year was significantly increased in patients with PAD (MACE, 30.0% vs. 15.8%, log rank test p<0.001; major bleeding, 6.7 vs. 3.6%, log rank test p=0.003, respectively) (Figure). Conclusion: Presence of PAD was strongly associated with higher rate of long-term MACE and major bleeding. These findings could have a clinical relevance in requiring individualized pharmacologic strategies to reduce the burden of cardiovascular disease. Funding Acknowledgement: Type of funding sources: None.